Bibliography
- Berg AH , CombsTP, DuX, BrownleeM, SchererPE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.Nature Med., 7, 947–953 (2001).
- Yamauchi T , KamonJ, MinokoshiYet al..: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med., 8, 1288–1295 (2002).
- Yu YH , GinsbergHN: Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue.Circ. Res., 96, 1042–1052 (2005).
- Chandran M , PhillipsSA, CiaraldiT, HenryRR: Adiponectin: more than just another fat cell hormone?Diabetes Care, 26, 2442–2450 (2003).
- Hotta K , FunahashiT, AritaYet al.. : Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 20, 1595–1599 (2000).
- Pischon T , GirmanCJ, HotamisligilGS, RifaiN, HuFB, RimmEB: Plasma adiponectin levels and risk of myocardial infarction in men.JAMA, 291, 1730–1737 (2004).
- Rothenbacher D , BrennerH, MarzW, KoenigW: Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers.Eur. Heart J., 26, 1640–1646 (2005).
- Pajvani UB , HawkinsM, CombsTPet al..: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem., 279, 12152–12162 (2004).
- Bruun JM , LihnAS, VerdichCet al..: Regulation of adiponectin by adipose-tissue derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metabol.285, E527–E533 (2003).
- Fasshauer M , KralischS, KlierMet al..: Adiponectin gene expression and seretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 301, 1045–1050 (2003).
- Okamoto Y , KiharaS, OuchiNet al..: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 106, 2767–2770 (2002).
- Yamauchi T , KamonJ, WakiHet al..: Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem., 278, 2461–2468 (2003).
- Kubota N , TerauchiY, YamauchiTet al..: Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem., 277, 25863–25866 (2002).
- Ouchi N , KiharaS, AritaYet al..: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100, 2473-2476 (1999).
- Arita Y , KiharaS, OuchiNet al..: Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 105, 2893–2898 (2002).
- Kumada M , KiharaS, SumitsujiSet al..: Osaka CAD Study Group. Coronary artery disease: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol., 23, 85–89 (2003).
- von Eynatten M , SchneiderJG, HumpertPMet al..: Lipoprotein lipase may link adiponectin with dyslipidemia and CAD (abstract). Circulation 108 (Suppl.), 624 (2003).
- Lindsay RS , ResnickHE, ZhuJet al..: Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol., 25, e15–e16 (2005).
- Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB: Adiponectin and future coronary heart disease events among men with Type 2 diabetes. Diabetes, 54, 534–539 (2005).
- Zoccali C , MallamaciF, TripepiGet al..: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end stage renal disease. J. Am. Soc. Nephrol., 13, 134–141 (2002).
- Maahs DM , OgdenLG, KinneyGLet al..: Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation, 111, 747–753 (2005).
- Grass DS , SainiU, FelknerRHet al..: Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. J. Lipid Res., 36, 1082–1091 (1995).
- Yamauchi T , KamonJ, WakiHet al..: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med., 7, 941–946 (2001).
- von Eynatten M , SchneiderJG, HumpertPMet al..: Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care, 27, 2925–2929 (2004).
- Taskinen MR : Lipoprotein lipase in diabetes.Diabetes Metab. Rev., 3, 551–570 (1987).
- Schneider JG , von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA: Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care, 28, 2181–2186 (2005).
- Cnop M , HavelPJ, UtzschneiderKMet al..: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459–469 (2003).
- Hogarth CA , RoyA, EbertDL: Genomic evidence for the absence of a functional cholesteryl ester transfer protein gene in mice and rats.Comp. Biochem. Physiol. B. Biochem. Mol. Biol., 135, 219–229 (2003).
- Barter PJ , BrewerHB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR: Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 23, 160–167 (2003).
- Miller M , RhyneJ, HamletteS, BirnbaumJ, RodriguezA: Genetics of HDL regulation in humans.Curr. Opin. Lipidol., 14, 273–279 (2003).
- Zheng XL , MatsubaraS, DiaoC, HollenbergMD, WongNC: Activation of apolipoprotein AI gene expression by protein kinase A and kinase C through transcription factor, Sp1.J. Biol. Chem., 275, 31747–31754 (2000).
- Ouchi N , KiharaS, AritaYet al..: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 102, 1296–1301 (2000).
- Nagashima K , LopezC, DonovanDet al..: Effects of the PPAR gamma agonist pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes mellitus. J. Clin Invest., 115, 1323–1332 (2005).
- Koh KK , QuonMJ, HanSHet al..: Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with Type 2 diabetes. Hypertension, 45, 1088–1093 (2005).